BMO Capital Initiates Coverage of HCA Healthcare at Outperform
Fintel reports that on September 23, 2026, BMO Capital initiated coverage of HCA Healthcare (NYSE:HCA) (LSE:0J1R) with a Outperform recommendation.
HCA Healthcare, Inc., based in the United States, operates as a leading health care services company within the hospital industry. It manages a network of facilities that includes 182 hospitals and approximately 2,300 ambulatory sites of care like surgery centers, freestanding ERs, urgent care centers, and physician clinics across 20 states and the United Kingdom. Key projects typically focus on expanding their service capacity and improving clinical outcomes through technology-driven solutions such as patient data analytics and advanced diagnostic tools. HCA Healthcare also emphasizes the integration of electronic health records to streamline operations. Their strategic initiatives often aim to enhance patient care and expand its geographic footprint while aligning with health care regulatory requirements.
Prior to this rating action, the stock closed at $438.12 on September 22, 2026. This latest close of $438.12 represents a price change of +3.37% over one week, relative to a baseline close of $423.82 on September 15, 2026. Over a one-month period, the stock experienced a price change of +2.08% from a baseline close of $429.19 on August 21, 2026.
The company's latest earnings report was released on July 24, 2026. HCA Healthcare reported actual earnings per share of 7.62, compared to the estimate of 7.5425, representing an earnings surprise of +1.03%. Actual revenue for the quarter reached $20,230,000,000.00, compared to the estimated revenue of $19,620,473,009.00.
As of September 15, 2026, the current consensus target mean for the stock was $462.28, with a median target of $451.35. This mean target represents an implied change of +5.51%. The prior consensus target mean was also $462.28 as of August 28, 2026, showing a consensus target revision of 0.00%.
For the recommendation period of September 1, 2026, the aggregate analyst recommendations consisted of 6 strong buy, 11 buy, 12 hold, 1 sell, and 0 strong sell ratings, totaling 30 recommendations. This breakdown reflects 56.7% positive, 40.0% hold, and 3.3% negative recommendations. These figures are identical to the prior recommendation period of August 1, 2026, which also recorded 6 strong buy, 11 buy, 12 hold, 1 sell, and 0 strong sell ratings across 30 total recommendations.
Other recent analyst actions include Leerink Partners, which maintained its Outperform rating on September 18, 2026, and RBC Capital, which reiterated its Outperform rating on September 8, 2026.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| September 23, 2026 | BMO Capital | Outperform | initiated coverage | |
| September 18, 2026 | Leerink Partners | Outperform | Outperform | maintained |
| September 8, 2026 | RBC Capital | Outperform | Outperform | reiterated |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.